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ngiographic Restenosis and
linical Recurrence After
irolimus- and Paclitaxel-
luting Stent Implantation*
ieter J. Vlaar, MSC, Felix Zijlstra, MD, PHD
roningen, the Netherlands
he coronary artery stent has succeeded in reducing procedural
omplications, restenosis, clinical recurrence, and revasculariza-
ions after percutaneous coronary interventions (PCI). In
round 90% of PCIs, a stent is implanted, of which the
ajority are drug-eluting stents (DES) (1). At the moment, 4
ES are approved by the U.S. Food and Drug Administration
or sale in the U.S.: the Cordis Cypher (Johnson & Johnson,
iami, Florida) sirolimus-eluting stent (SES), Boston Scien-
ific Taxus Express2 (Natick, Massachusetts) paclitaxel-eluting
tent (PES), Medtronic Endeavor (Minneapolis, Minnesota)
otarolimus-eluting, and the Abbott/Boston Scientific Xience
/Promus everolimus-eluting stent. Besides the type of anti-
roliferative agent, these stents differ on major points, includ-
ng the architecture of the stent itself and the manner in which
he drug is embedded and released. Each of these characteris-
ics can theoretically cause differences in efficacy and safety. For
hat reason, it is important to investigate the performance of
hese stents in the setting of both randomized trials and
egistries.
See page 767
As SES and PES were for almost 5 years the only
pproved DES in the U.S., they are the most widely tested
tents in a variety of patient subsets. At the moment, around
0 randomized controlled trials (which included a total of
10,000 patients) and several meta-analyses have been
ublished comparing the SES and PES in a head-to-head
ashion (2–8). The majority of these trials performed
rotocol-mandated follow-up angiography to assess angio-
raphic restenosis and late luminal loss after stent implan-
ation using automated edge detection systems (quantitative
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.t
From Department of Cardiology, University Medical Center Groningen, Thorax
enter, Groningen, the Netherlands.oronary analysis). In these trials (Table 1), which included
total of 5,765 patients, SES were associated with substan-
ially less angiographic in-stent restenosis and late luminal
oss than were PES (Figs. 1 and 2). However, the lingering
uestion remains whether this better ability to reduce
eointima proliferation also translates into a lower rate of
ecurrence of ischemic symptoms mandating reintervention
clinical recurrence).
Two recent meta-analyses comparing SES and PES
ound a significant reduction of the risk of target lesion
evascularizations (TLR) associated with SES as compared
ith PES (2,3). However, the majority of the included trials
n these meta-analyses performed protocol-mandated
ollow-up angiography, which may have resulted in more
evascularizations in the PES group through the “oculo-
tenotic reflex” (9). Data supporting this hypothesis come
rom the SORT OUT II (Danish Organization on Ran-
omized Trials with Clinical Outcome) trial (8). This trial
as adequately powered for clinical events and did not
nclude routine angiography during follow-up. As part of
his trial, 2,098 unselected patients were randomized to SES
r PES. During follow-up, repeat angiography was driven
y clinical recurrence. At 9-month follow-up, there was no
ifference between the SES and PES group regarding major
dverse cardiac events (10.0% vs. 11.6%, p  NS) or TLR
4.5% vs. 5.9%, p  NS). The results of this trial suggest
hat, in contradistinction to what the angiographic data
ould suggest, the difference between the 2 types of stents
n an unselected population is of limited clinical relevance.
uture stent trials should aim to provide more data on the
linical impact of restenosis: for example, by integrating the
outine use of fractional flow reserve measurements during
ollow-up angiographies to function as gatekeepers of rein-
erventions (10).
Beside randomized controlled trials, registries can offer
mportant information on the possible clinical differences
etween SES and PES in routine practice. The 2 largest
ublished registries comparing PES with SES are the
CAAR (Swedish Coronary Angiography and Angioplasty
egistry) (11) and WDHR (Western Denmark Heart
egistry) (12) databases. The SCAAR registry included
9,004 patients undergoing PCI in Sweden between 2004
nd 2008. The primary end point was clinically driven
estenosis rate, defined as angiographically significant reste-
osis detected at any repeat angiography performed for
schemic symptoms. After 1 and 2 years, there were no
ignificant differences in restenosis rates between SES (3.3%
nd 4.9%, respectively) and PES (3.7% and 5.1%, respec-
ively). No difference in survival between the 2 types of
tents was found. In contrast, the WDHR registry included
2,395 consecutive patients undergoing PCI and found
arge differences in terms of stent thrombosis, mortality,
einfarction, and revascularization rates between the 2 stent
ypes. The results of the WHDR registry are in contrast
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777ith available randomized data on SES versus PES that
howed no difference in mortality and reinfarction be-
ween the 2 types of stents (2,3). In addition, previous
nalyses of the SCAAR registry on bare-metal stents
ersus DES caused confusion as they suggested a late-
Figure 1. Late Luminal Loss After SES and PES Implantation
Late luminal loss after SES and PES implantation in trials with protocol
mandated follow-up angiography. *In-segment instead of in-stent late lumi-
Table 1. Randomized Controlled Trials With Protocol-Mandated Follow-Up A
Trial/Author (Ref. #) n Population
DES-DIABETES (4) 400 DM
DiabeDES (5) 153 DM
Kim et al. (6) 169 DM
ISAR-DIABETES (3) 250 DM
ISAR-DESIRE (3) 200 ISR
ISAR-SMART III (3) 360 Small, non-DM
LONG DES II (3) 500 Long lesions
Pan et al. (7) 205 Bifurcation lesions
Petronio et al. (3) 100 Complex lesions
Cervinka et al. (3) 70 Complex lesions
CORPAL (3) 652 Complex lesions
PROSIT (3) 308 AMI
REALITY (3) 1,386 Unselected
SIRTAX (3) 1,012 Unselected
— not available; AMI acute myocardial infarction; CORPAL Drug-Eluting Stents for Comple
Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus trial; Diab
for In-Stent Restenosis trial; ISAR-DIABETES Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Sten
Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries trial; ISR in-stent restenosis; LONG
in the Treatment of Long Native Coronary Lesions trial; PES  paclitaxel-eluting stent(s); PROSIT 
ST-ElevationMyocardial Infarction trial; REALITY Prospective RandomizedMulti-Center Head-to-H
sirolimus-eluting stent(s); SIRTAX Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stennal loss. Abbreviations as in Table 1.ccurring increase in mortality after DES implantation
13). The sometimes conflicting and confusing results of
hese registries demonstrate that nonrandomized data,
ven from carefully controlled registries, should be inter-
reted with caution.
Figure 2. In-Stent Restenosis Rates of SES and PES
In-stent restenosis rates of SES and PES in trials with protocol-mandated
follow-up angiography. *In-segment instead of in-stent restenosis. Abbrevi-
raphy
Time to Follow-Up
Angiography
Follow-Up Angiography
Available (%)
PES SES PES SES
188 days 187 days 77 88
8 months 8 months 82 88
6 months 6 months 100 100
196 days 196 days 82 82
197 days 197 days 92 91
196 days 196 days 86 88
186 days 188 days 82 84
8 months 8 months 55 51
9 months 9 months 86 84
6 months 6 months 100 97
— — — —
197 days 210 days 75 78
8 months 8 months 89 91
8 months 8 months 54 53
s: Randomized Rapamycin Versus Paclitaxel trial; DES-DIABETES A Randomized Comparison of
Diabetes and Drug-Eluting Stent trial; DM diabetes mellitus; ISAR-DESIRE Drug-Eluting Stents
Prevention of Restenosis in Diabetic Patients With Coronary Artery Disease trial; ISAR-SMART 3
Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent
ective Randomized Trial of Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Acute
mparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus) trial; SES
onary Revascularization trial.ngiog
x Lesion
eDES
t for the
DES II
Prosp
ead Coations as in Table 1.
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778In this issue of JACC: Cardiovascular Interventions, No-
ack et al. (14) present data of another large registry. The
VENT (Evaluation of Drug Eluting Stents and Ischemic
vents) registry included 6,035 unselected patients who
nderwent PCI with either SES (n  3,443) or PES (n 
,592) at 47 centers in the U.S. At 1-year follow-up, there
as a significantly higher TLR rate for SES than for PES
4.4% vs. 3.3%, p 0.020), which remained significant after
djustment for clinical, angiographic, and procedural char-
cteristics. No significant differences between the 2 types of
tents were found in terms of cardiac death, reinfarction, or
tent thrombosis. Novack et al. (14) also investigated the
mpact of stent preference at the site level on clinical
utcomes. This was done by dividing the 47 participating
enters into 3 equal groups based on the proportion of DES
mplanted during the study period that were SES. Interest-
ngly, after adjusting for site-level stent preference, the
bserved adjusted difference in TLR between SES and PES
as no longer present. Operator and center preference for a
pecific treatment or device is an important confounder in
etrospective analyses and registries. The finding of Novack
t al. (14) emphasizes this and further underscores some of
he fundamental limitations of registries.
In conclusion, there is no evidence that SES is associated
ith a relevant reduction in clinical recurrence as compared
ith PES. Further randomized controlled trials will be
ecessary to investigate the impact of new generation DES
n clinical events.
eprint requests and correspondence: Pieter J. Vlaar, Depart-
ent of Cardiology, University Medical Center Groningen, Han-
eplein 1, Thorax Center, 9713 AV Groningen, Groningen, the
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